Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 7:21 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 793–816 of 1,789 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Intervention 2 - Sham Treatment Clear all

Conditions: Alcohol Drinking, Alcohol Intoxication, Alcoholism
Interventions: Brain stimulation with mindfulness-based relapse prevention; Device
Lead sponsor: University of New Mexico; Other
Eligibility: 18 Years and older
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Albuquerque, New Mexico

Conditions: Migraine
Interventions: Fremanezumab, Placebo; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 1,130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 179
States / cities: Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 77 more

Conditions: Delayed Sleep-Wake Phase Disorder
Interventions: Light and Citalopram; Combination Product
Lead sponsor: Northwestern University; Other
Eligibility: 16 Years and older
Enrollment: 220 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Chronic Kidney Disease, Stage 4, Chronic Kidney Disease, Stage 5, EBV-Related Lymphoproliferative Disorder, EBV-Related Malignant Neoplasm, Post-Transplant Lymphoproliferative Disorder
Interventions: Biospecimen Collection, Dulbecco''s Phosphate-Buffered Saline, Peptide Vaccine, QS21; Procedure · Drug · Biological
Lead sponsor: Ohio State University Comprehensive Cancer Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 55 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Migraine
Interventions: DC Stimulator (Transcranial Direct Current Stimulator); Device
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Healthy
Interventions: positive psychological intervention, Active control condition; Behavioral
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years and older
Enrollment: 250 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Prader-Willi Syndrome
Interventions: Oxytocin, Placebo; Drug
Lead sponsor: University of Florida; Other
Eligibility: 1 Week to 6 Months
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Shoulder Pain, Chronic Pain, Musculoskeletal Injury
Interventions: Dry Needling, Sham Dry Needling; Device · Other
Lead sponsor: Army-Baylor University Doctoral Program in Physical Therapy; Other
Eligibility: 18 Years to 50 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Head and Neck Squamous Cell Carcinoma, Head and Neck Cancer
Interventions: Tadalafil, Anti-MUC1 Vaccine, Anti-Influenza Vaccine, Tadalafil Placebo, Anti-MUC1 Vaccine Placebo, Standard of Care Treatment, Anti-Influenza Vaccine Placebo; Drug · Biological · Other
Lead sponsor: Donald T. Weed, MD, FACS; Other
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Schizophrenia, Schizophrenia Schizoaffective
Interventions: PLIFUS, Sham PLIFUS, MRI; Device
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 50 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 2
States / cities: Brooklyn, New York • New York, New York

Conditions: Pain, Acute
Interventions: Intravenous oxytocin, Intravenous placebo, Intranasal oxytocin, Intranasal placebo; Drug
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years to 75 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Obstructive Sleep Apnea
Interventions: Conservative Medical Therapy (CMT), Sham PAP (Sham), Active PAP with RT Support (Active-Beh), Active PAP with Behavioral Modification (Active+Beh); Behavioral · Device
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 45 Years to 75 Years
Enrollment: 169 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Rosacea
Interventions: Brimonidine 0.33% gel (Br), CD07805/47 (Br) placebo gel, Ivermectin 1% cream (IVM), CD5024 (IVM) placebo cream; Drug · Other
Lead sponsor: Galderma R&D; Industry
Eligibility: 18 Years and older
Enrollment: 190 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 7
States / cities: Fort Smith, Arkansas • Rogers, Arkansas • Sacramento, California + 4 more

Conditions: Congenital Cystic Adenomatoid Malformation
Interventions: Betamethasone, Placebo; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older · Female only
Enrollment: 1 participant
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2011
U.S. locations: 3
States / cities: San Francisco, California • Cincinnati, Ohio • Philadelphia, Pennsylvania

Conditions: Healthy
Interventions: Whole grain oats and barley; Other
Lead sponsor: Tufts University; Other
Eligibility: 40 Years to 70 Years
Enrollment: 13 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Flushing, Alcohol-Related Disorders, Aldehyde Dehydrogenase Deficiency
Interventions: Brimonidine Tartrate, Placebo Vehicle Gel; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 21 Years and older
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Anxiety State
Interventions: Aromatherapy, Placebo; Other
Lead sponsor: University of Miami; Other
Eligibility: 18 Years to 85 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Rhinosinusitis Chronic, Sinus Cancer, Sinus Polyp, Encephalocele
Interventions: Tranexamic acid injection, Total Intravenous Anesthesia, Inhalational isoflurane; Drug
Lead sponsor: Our Lady of the Lake Hospital; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Baton Rouge, Louisiana

Conditions: Alzheimer Disease
Interventions: PF-04494700 - Low Dose Arm, PF-04494700 - High Dose Arm, Placebo Comparator; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 50 Years and older
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 12
States / cities: Sun City, Arizona • Fresno, California • San Diego, California + 9 more

Conditions: Pain, Phlebotomy, Palliative Care
Interventions: Synera (lidocaine 70mg/tetracaine 70mg); Drug
Lead sponsor: US Oncology Research; Industry
Eligibility: 18 Years and older
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Parkinson's Disease
Interventions: Transcranial direct current stimulation; Device
Lead sponsor: Spaulding Rehabilitation Hospital; Other
Eligibility: 40 Years to 90 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2013
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Chronic Pancreatitis
Interventions: Indomethacin, Placebo, Endoscopy for Pancreatic Function Testing; Drug · Procedure
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 60 Years
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 2
States / cities: Rochester, Minnesota • Columbus, Ohio

Conditions: Pain
Interventions: 2% lidocaine gel, placebo; Drug · Other
Lead sponsor: Columbia University; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: New York, New York

Conditions: Wet Macular Degeneration
Interventions: KSI-301, Aflibercept, Sham Procedure; Drug · Other
Lead sponsor: Kodiak Sciences Inc; Industry
Eligibility: 50 Years and older
Enrollment: 559 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 59
States / cities: Phoenix, Arizona • Springdale, Arkansas • Bakersfield, California + 53 more

Search by objective public record fields.

Mindfulness-Based Intervention and Transcranial Direct Current Brain Stimulation to Reduce Heavy Drinking

Comparing Efficacy and Safety of 2 Dose Regimens of Subcutaneous Administration of TEV-48125 Versus Placebo for the Preventive Treatment of Chronic Migraine

Pupillometry in Delayed Sleep Wake Phase Disorder

BZLF1 Peptide Vaccine (OSU-2131) With QS-21 for the Prevention of Epstein-Barr Virus Related Cancer in Patients Awaiting Solid Organ Transplants

Migraine--Investigational Treatment of Migraine With Noninvasive Brain Stimulation. (tDCS- Migraine)

Writing Activities and Emotions

Intranasal Oxytocin for Infants With Prader-Willi Syndrome

Feasibility of Near-infrared Spectroscopy to Measure Cortical Pain Pathway (Brain) Activation During Dry Needling

PDE5 Inhibition Via Tadalafil to Enhance Anti-Tumor Mucin 1 (MUC1) Vaccine Efficacy in Patients With HNSCC

Focused Ultrasound Modulation of the Globus Pallidus Interna in Schizophrenia

Intranasal and Intravenous Oxytocin for Analgesia to Noxious Heat Pain

Sleep Apnea Intervention for Cardiovascular Disease Reduction

MirvasO Soolantra Association In the Treatment of Moderate to Severe rosaCea.

Prenatal Steroids for Treatment of Congenital Cystic Adenomatoid Malformations (CCAM)

Clinical Assessment of Barley and Oat Phytochemicals

Treatment of Asian Flushing Syndrome With Topical Alpha Agonists

Aromatherapy Effect on Anxiety Prior to Ultrasound Guided Musculoskeletal Procedures

TIVA vs TXA in Sinus Surgery to Evaluate Operative Blood Loss and Surgical Field Quality

A Safety and Tolerability Evaluation of Two 10-Week Dose Regimens of Orally-Administered PF-04494700 in Alzheimer's Patients

Synera Venipuncture Pain

Use of Noninvasive Brain Stimulation in Parkinson's Disease

Trial of Indomethacin in Chronic Pancreatitis

Intracervical Lidocaine Gel for IUD Insertional Pain

A Study to Evaluate the Efficacy and Safety of KSI-301, an Anti-VEGF Antibody Biopolymer Conjugate, Versus Aflibercept in Patients With Neovascular (Wet) Age-Related Macular Degeneration.